AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00998010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + temozolomide+ radiation therapy
Description: Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
Study NCT03830580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive stimulation (singing)
Description: A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
Study NCT02901886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Description: The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
Study NCT03759990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lean
Description: Videolaryngoscope used in intubation
Study NCT03759990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: obese
Description: Videolaryngoscope used in intubation
Study NCT01865487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56ug/IC31nmol
Description: H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
Study NCT01865487 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
Study NCT01441388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus VEGF inhibitor combinations
Description: Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
Study NCT03355820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for antibody determination
Description: In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
Study NCT01409330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: 8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
Study NCT01700985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Applied twice daily for two weeks
Study NCT03140423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1. Routine Care (Mupirocin/CHG)
Description: The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
Study NCT03788590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jenscare TAVI
Description: Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
Study NCT01675895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine lidocaine spinal anesthesia
Description: Spinal anesthesia
Study NCT01675895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine Spinal anesthesia
Description: spinal anesthesia
Study NCT03140423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2. Iodophor/CHG Decolonization
Description: The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
Study NCT02534194 — intervention group
Intervention type: OTHER
Intervention: Image acquisition
Description: Images of baby's face (including ear) and feet
Study NCT00895193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple pectin
Description: Apple pectin 2000mg
Study NCT00895193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325 mg
Description: Aspirin 325 mg
Study NCT00895193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03095053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive chromosome screening
Description: Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA).
Study NCT05283863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation
Description: Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
Study NCT05283863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-frequency stimulation
Description: Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
Study NCT03169244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
Study NCT03169244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo will be initiated on Day 1 and continue throughout the course of the study.
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: weight lifting to increase muscle strength
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: weight lifting to increase muscle strength
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: treadmill walking to increase endurance
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: treadmill walking to increase endurance
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: stretches to improve flexibility
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: stretches to improve flexibility
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Specific timing and coordination training
Description: stepping and walking patterns to improve timing and coordination of gait
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity behavioral intervention
Description: Intervention to encourage participants to be more physically active
Study NCT02663778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention
Description: Intervention to encourage participants to be more physically active
Study NCT03265886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warm bupivacaine at (37°c)
Description: Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
Study NCT03265886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine at operating room temperature (23°c)
Description: Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
Study NCT03639519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated orange beverage
Description: The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
Study NCT03144102 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality-based therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
Study NCT03144102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
Study NCT03144102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal transcranial direct-current stimulation (tDCS)
Description: Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
Study NCT03144102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct-current stimulation (tDCS)
Description: Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
Study NCT03144102 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Occupational Therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
Study NCT03144102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy for upper-limbs motor rehabilitation
Description: During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
Study NCT03144102 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct-current stimulation (tDCS)
Description: Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
Study NCT01366378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylnaltrexone
Study NCT03331237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scalene block
Description: scalene block using 5ml of ropivacaine
Study NCT03331237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISO block
Description: ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
Study NCT01322126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound probe
Description: we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
Study NCT02059720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSCT
Description: Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
Study NCT01274806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Core Stability Exercise, Endurance training, recovery massage
Study NCT01369017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
Study NCT01369017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of NS
Study NCT04235699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and Dietary Manipulation
Description: Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
Study NCT03832699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG
Description: Oral progesterone 10 mg TID
Study NCT03832699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin 100Mg Vaginal Insert
Description: Vaginal Endometrin 100 mg twice daily
Study NCT00995085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metadoxine
Description: one oral 1400mg dose (2 tablets)
Study NCT01314378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Eight session intensive behavioral training program for smokers
Study NCT01314378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Eight session intensive behavioral intervention for smokers
Study NCT02516904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101 IV
Description: antifungal
Study NCT02516904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo therapy session conducted by a speech pathologist
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo therapy session conducted by a speech pathologist
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Perform prescribed home exercises
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Perform prescribed home exercises
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training
Description: Participate in EMST
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03175289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05283863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
Study NCT01917448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine 0.15 mg
Study NCT01917448 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: Patient receive only local infiltration without spinal analgesia
Study NCT01441388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus axitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study NCT05283863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
Study NCT01441388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus sunitinib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study NCT02365779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral laparoscopic salpingectomy
Description: Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
Study NCT02365779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endomicroscopy Cellvizio® system
Study NCT01441388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus bevacizumab
Description: Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
Study NCT01441388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib plus sorafenib
Description: Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
Study NCT02319486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin periocular injection
Description: chemotherapy together with/without 20mg/2ml carboplatin periocular injection
Study NCT02319486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEV chemotherapy
Description: vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
Study NCT03508518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared care device in psychiatry (DSPP)
Description: The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
Study NCT01883024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A decision support software
Study NCT01883024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Insulin Pump
Study NCT01883024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous glucose monitoring
Study NCT00099021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: Given PO
Study NCT01409330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet intervention
Description: 8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
Study NCT01077570 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
Study NCT04447651 — intervention group
Intervention type: OTHER
Intervention: Recommendation for treatment with immunotherapy
Description: Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
Study NCT02098967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Non-escalating IV doses given on Days 1-5 of Cycle 1.
Study NCT02098967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Study NCT02098967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6839921
Description: Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
Study NCT03441308 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational method of group treatment
Study NCT03441308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational method of group treatment
Study NCT02807363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 4-mg QD
Description: 4-mg Leuprolide oral tablet once daily for 28 consecutive days.
Study NCT02807363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 4-mg BID
Description: 4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
Study NCT02807363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Depot
Description: 3.75 mg intramuscular depot injection
Study NCT02807363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet 10-mg BID
Description: 10-mg Leuprolide oral tablet twice daily for 28 consecutive days.